Literature DB >> 18495821

Fractalkine in rheumatoid arthritis: a review to date.

G Murphy1, N Caplice, M Molloy.   

Abstract

Rheumatoid arthritis (RA) is characterized by the expansion of the synovium, with infiltration of pro-inflammatory cells, neovascularization and an abundance of pro-inflammatory cytokines resulting in tissue destruction and bone erosion. Fractalkine (FKN), a recently described chemokine, possesses chemotactic, angiogenic and adhesive functions that associates it with all of these destructive processes. In this review, we describe the research to date, which implicates FKN and its receptor in the pathogenesis of RA and propose that this molecule may represent a future therapeutic target for RA.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18495821     DOI： 10.1093/rheumatology/ken197

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


  11 in total

1.  Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells.

Authors:  Isabell Hamann; Nadine Unterwalder; Astrid E Cardona; Christian Meisel; Frauke Zipp; Richard M Ransohoff; Carmen Infante-Duarte
Journal:  Immunology       Date:  2011-02-14       Impact factor: 7.397

Review 2.  Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.

Authors:  Beatrix Bartok; Gary S Firestein
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

3.  JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis.

Authors:  Monica Guma; Lisa M Ronacher; Gary S Firestein; Michael Karin; Maripat Corr
Journal:  Arthritis Rheum       Date:  2011-06

4.  Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome.

Authors:  Tsuyoshi Kasama; Hidekazu Furuya; Ryo Yanai; Kumiko Ohtsuka; Ryo Takahashi; Nobuyuki Yajima; Yusuke Miwa; Kazuo Kobayashi
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

5.  Retinal vascular repair and neovascularization are not dependent on CX3CR1 signaling in a model of ischemic retinopathy.

Authors:  Lian Zhao; Wenxin Ma; Robert N Fariss; Wai T Wong
Journal:  Exp Eye Res       Date:  2009-01-07       Impact factor: 3.467

Review 6.  Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Akiko Kobayashi; Hisashi Yamanaka
Journal:  J Biomed Biotechnol       Date:  2010-06-29

7.  Phagocytosis inhibits F-actin-enriched membrane protrusions stimulated by fractalkine (CX3CL1) and colony-stimulating factor 1.

Authors:  Yong Luo; Beth M Isaac; Arturo Casadevall; Dianne Cox
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

8.  c-Jun N-Terminal Kinase in Inflammation and Rheumatic Diseases.

Authors:  Monica Guma; Gary S Firestein
Journal:  Open Rheumatol J       Date:  2012-09-07

Review 9.  Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies.

Authors:  Elisa Ferretti; Vito Pistoia; Anna Corcione
Journal:  Mediators Inflamm       Date:  2014-03-30       Impact factor: 4.711

10.  Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis.

Authors:  Michihito Sato; Kumiko Ohtsuka; Ryo Takahashi; Kuninobu Wakabayashi; Tsuyoshi Odai; Takeo Isozaki; Nobuyuki Yajima; Yusuke Miwa; Tsuyoshi Kasama
Journal:  Open Access Rheumatol       Date:  2011-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.